BFLY:NYE-Butterfly Network Inc (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 3.06

Change

+0.01 (+0.33)%

Market Cap

USD 0.61B

Volume

3.30M

Avg Analyst Target

USD 7.00 (+128.76%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Butterfly Network Inc (BFLY) Stock Analysis:
Based on the Butterfly Network Inc stock forecasts from 2 analysts, the average analyst target price for Butterfly Network Inc is USD 7.00 over the next 12 months. Butterfly Network Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Butterfly Network Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Butterfly Network Inc’s stock price was USD 3.06. Butterfly Network Inc’s stock price has changed by +13.75% over the past week, -26.97% over the past month and -69.09% over the last year.

About

Butterfly Network, Inc., a digital health company, develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+, a point-of-care ul ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABT Abbott Laboratories

-0.17 (-0.15%)

USD192.39B 25.51 14.94
MDT Medtronic plc

+1.14 (+1.11%)

USD137.74B 28.29 17.05
SYK Stryker Corporation

+0.58 (+0.25%)

USD88.21B 44.36 27.69
EW Edwards Lifesciences Corporati..

-1.62 (-1.66%)

USD60.65B 40.14 29.86
BSX Boston Scientific Corporation

+0.16 (+0.40%)

USD56.70B 74.83 25.48
ZBH Zimmer Biomet Holdings Inc

+0.05 (+0.04%)

USD24.12B 60.18 18.95
STE STERIS plc

+1.76 (+0.81%)

USD21.65B 73.11 29.25
PHG Koninklijke Philips N.V

+0.37 (+1.52%)

USD20.25B 6.33 47.28
BIO-B Bio-Rad Laboratories Inc

N/A

USD15.05B 3.59 2.64
BIO Bio-Rad Laboratories Inc

-3.02 (-0.60%)

USD14.96B 3.61 2.64

ETFs Containing BFLY

Symbol Name Weight Mer Price(Change) Market Cap
DSPC The De-SPAC ETF 0.00 % 0.75 %

-0.31 (-3.26%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -54.26% 21% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.26% 21% F 4% F
Trailing 12 Months  
Capital Gain -68.42% 19% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.42% 19% F 4% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -14.15% 7% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.15% 7% F 4% F
Risk Return Profile  
Volatility (Standard Deviation) 29.13% 48% F 38% F
Risk Adjusted Return -48.57% 7% F 5% F
Market Capitalization 0.61B 28% F 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.48 83% B 53% F
Price / Cash Flow Ratio -3.22 83% B 83% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -14.51% 28% F 12% F
Return on Invested Capital -649.96% 3% F 1% F
Return on Assets -30.13% 17% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 11.02 10% F 3% F
Short Percent 14.77% 7% F 24% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.